LTC1280540I2 - Modifikuotas VIII faktorius - Google Patents

Modifikuotas VIII faktorius

Info

Publication number
LTC1280540I2
LTC1280540I2 LTPA2016014C LTPA2016014C LTC1280540I2 LT C1280540 I2 LTC1280540 I2 LT C1280540I2 LT PA2016014 C LTPA2016014 C LT PA2016014C LT PA2016014 C LTPA2016014 C LT PA2016014C LT C1280540 I2 LTC1280540 I2 LT C1280540I2
Authority
LT
Lithuania
Prior art keywords
factor viii
modified factor
inhibitory antibodies
amino acid
modified
Prior art date
Application number
LTPA2016014C
Other languages
English (en)
Lithuanian (lt)
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Publication of LTC1280540I2 publication Critical patent/LTC1280540I2/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/10—Factor VIII, AHF; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Glass Compositions (AREA)
  • Fish Paste Products (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
LTPA2016014C 2000-03-10 2016-05-06 Modifikuotas VIII faktorius LTC1280540I2 (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/523,656 US6458563B1 (en) 1996-06-26 2000-03-10 Modified factor VIII
PCT/US2001/005076 WO2001068109A1 (en) 2000-03-10 2001-02-16 Modified factor viii

Publications (1)

Publication Number Publication Date
LTC1280540I2 true LTC1280540I2 (lt) 2020-05-25

Family

ID=24085870

Family Applications (1)

Application Number Title Priority Date Filing Date
LTPA2016014C LTC1280540I2 (lt) 2000-03-10 2016-05-06 Modifikuotas VIII faktorius

Country Status (35)

Country Link
US (3) US6458563B1 (OSRAM)
EP (1) EP1280540B1 (OSRAM)
JP (1) JP4044337B2 (OSRAM)
KR (1) KR100485525B1 (OSRAM)
CN (1) CN1191360C (OSRAM)
AT (1) ATE391512T1 (OSRAM)
AU (2) AU3841601A (OSRAM)
BE (1) BE2016C024I2 (OSRAM)
BR (2) BRPI0109131B8 (OSRAM)
CA (1) CA2400295C (OSRAM)
CY (2) CY1108179T1 (OSRAM)
CZ (1) CZ298250B6 (OSRAM)
DE (1) DE60133541T2 (OSRAM)
DK (1) DK1280540T3 (OSRAM)
EE (1) EE05075B1 (OSRAM)
ES (1) ES2304379T3 (OSRAM)
FR (1) FR16C0016I2 (OSRAM)
HU (2) HU227804B1 (OSRAM)
IL (2) IL151371A0 (OSRAM)
LT (1) LTC1280540I2 (OSRAM)
LU (1) LU93049I2 (OSRAM)
ME (1) MEP8209A (OSRAM)
MX (1) MXPA02008798A (OSRAM)
NL (1) NL300808I2 (OSRAM)
NO (2) NO331935B1 (OSRAM)
NZ (1) NZ520799A (OSRAM)
PL (1) PL202936B1 (OSRAM)
PT (1) PT1280540E (OSRAM)
RS (1) RS50364B (OSRAM)
RU (1) RU2285724C2 (OSRAM)
SI (1) SI1280540T1 (OSRAM)
SK (1) SK286205B6 (OSRAM)
UA (1) UA75064C2 (OSRAM)
WO (1) WO2001068109A1 (OSRAM)
ZA (1) ZA200206810B (OSRAM)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
JP2005518181A (ja) * 2001-01-12 2005-06-23 ジ・アメリカン・ナショナル・レッド・クロス 第ｖｉｉｉ因子のヘパラン硫酸プロテオグリカン仲介性クリアランスを低下させるための方法および組成物
JP4634036B2 (ja) * 2001-10-05 2011-02-16 エクスプレッション セラピューティクス， エルエルシー 高レベルエキスプレッサー第ｖｉｉｉ因子ポリペプチドをコードする核酸配列およびアミノ酸配列および使用方法
AU2002364509A1 (en) * 2001-11-30 2003-06-17 Emory University Factor viii c2 domain variants
GB0207092D0 (en) * 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7498024B2 (en) * 2003-06-03 2009-03-03 Cell Genesys, Inc. Compositions and methods for enhanced expression of immunoglobulins from a single vector using a peptide cleavage site
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
WO2005000891A2 (en) * 2003-06-26 2005-01-06 Merck Patent Gmbh Thrombopoietin proteins with improved properties
US20050059023A1 (en) * 2003-09-16 2005-03-17 Cantor Thomas L. Methods and kits for monitoring resistance to therapeutic agents
US7211559B2 (en) * 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
ATE463572T1 (de) * 2003-12-03 2010-04-15 Univ Rochester Rekombinanter faktor viii mit erhöhter spezifischer aktivität
DK1750733T3 (da) * 2004-05-03 2014-01-20 Univ Emory FREMGANGSMÅDE TIL INDGIVELSE AF SVINE-B-DOMÆNELØS fVIII
WO2005123928A1 (en) * 2004-06-08 2005-12-29 Battelle Memorial Institute Production of human coagulation factor viii from plant cells and whole plants
SI2363414T1 (sl) * 2004-11-12 2022-09-30 Bayer Healthcare Llc Usmerjena modifikacija FVIII
WO2006063031A2 (en) * 2004-12-06 2006-06-15 Haplomics Allelic variants of human factor viii
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
CN101379077A (zh) 2005-12-07 2009-03-04 夏洛特·豪泽 因子ⅷ和因子ⅷ-类似蛋白的小肽或者拟肽亲合性配体
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
WO2007115724A2 (en) * 2006-04-11 2007-10-18 Csl Behring Gmbh Method of increasing the in vivo recovery of therapeutic polypeptides
US7939632B2 (en) * 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
EP1935430A1 (en) * 2006-12-22 2008-06-25 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
AU2007338298B2 (en) * 2006-12-22 2013-02-07 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
FR2913020B1 (fr) * 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
EP1988101A1 (en) 2007-05-04 2008-11-05 Novo Nordisk A/S Improvement of factor VIII polypeptide titers in cell cultures
CN101965409A (zh) * 2007-11-01 2011-02-02 罗切斯特大学 具有增加的稳定性的重组因子viii
EP2149603A1 (en) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
US20110046060A1 (en) 2009-08-24 2011-02-24 Amunix Operating, Inc., Coagulation factor IX compositions and methods of making and using same
ES2730800T3 (es) 2009-02-03 2019-11-12 Amunix Pharmaceuticals Inc Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
DK2440239T3 (en) 2009-06-09 2017-10-16 Prolong Pharmaceuticals Llc HEMOGLOBIN FORMATIONS
WO2011060371A2 (en) * 2009-11-13 2011-05-19 Puget Sound Blood Center Factor viii t cell epitope variants having reduced immunogenicity
EP4382170A3 (en) 2009-12-06 2024-09-04 Bioverativ Therapeutics Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
US20110177107A1 (en) * 2010-01-14 2011-07-21 Haplomics, Inc. Predicting and reducing alloimmunogenicity of protein therapeutics
DK2591099T3 (da) 2010-07-09 2021-02-15 Bioverativ Therapeutics Inc Kimære koagulationsfaktorer
WO2012006623A1 (en) 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Systems for factor viii processing and methods thereof
WO2012061689A2 (en) * 2010-11-05 2012-05-10 Ipsen Pharma S.A.S. A new variant of antihemophilic factor viii having increased specific activity
JP2014504870A (ja) * 2011-01-05 2014-02-27 エクスプレッション セラピューティクス， エルエルシー 高収率懸濁細胞株、システム、およびその製造方法
PT2717898T (pt) 2011-06-10 2019-05-20 Bioverativ Therapeutics Inc Compostos pró-coagulantes e processos para a sua utilização
AU2012282875B2 (en) 2011-07-08 2016-04-21 Bioverativ Therapeutics Inc. Factor VIII chimeric and hybrid polypeptides, and methods of use thereof
EP2737311B1 (en) 2011-07-25 2020-12-02 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
CN102277379B (zh) * 2011-08-18 2013-07-24 中国科学院遗传与发育生物学研究所 表达凝血因子viii的表达载体及其应用
ES2753124T3 (es) 2012-01-12 2020-04-07 Bioverativ Therapeutics Inc Polipéptidos quiméricos de factor VIII y usos de los mismos
ES2700583T3 (es) 2012-01-12 2019-02-18 Bioverativ Therapeutics Inc Procedimientos para reducir la inmunogenicidad contra el Factor VIII en individuos sometidos a terapia con Factor VIII
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
DK2814840T3 (da) 2012-02-15 2020-02-03 Bioverativ Therapeutics Inc Faktor viii-sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf
EP2666782A1 (en) * 2012-05-22 2013-11-27 Imnate Sarl Coagulation factor VIII with reduced immunogenicity.
WO2013185113A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Procoagulant compounds
HK1207591A1 (en) 2012-06-08 2016-02-05 Biogen Ma Inc. Chimeric clotting factors
US10023628B2 (en) 2012-07-06 2018-07-17 Bioverativ Therapeutics Inc. Cell line expressing single chain factor VIII polypeptides and uses thereof
DK2882450T3 (da) 2012-07-11 2020-02-24 Bioverativ Therapeutics Inc Faktor viii-kompleks med xten og von willebrand-faktorprotein samt anvendelser deraf
US10001495B2 (en) 2012-07-25 2018-06-19 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
WO2014063108A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
EP3943102A1 (en) 2012-10-30 2022-01-26 Bioverativ Therapeutics Inc. Methods of using fviii polypeptide
EP2928303A4 (en) 2012-12-07 2016-07-13 Haplomics Inc FACTOR VIII MUTATION REPAIR AND TOLERANCE INDUCTION
FI2956477T4 (fi) 2013-02-15 2024-04-24 Bioverativ Therapeutics Inc Optimoitu tekijä viii:n geeni
TWI828269B (zh) 2013-03-15 2024-01-01 美商百歐維拉提夫治療公司 因子ix多肽調配物
EP4122487A1 (en) 2013-03-15 2023-01-25 Bioverativ Therapeutics Inc. Factor viii polypeptide formulations
MX2015016567A (es) 2013-06-28 2016-03-31 Biogen Ma Inc Enlazador escindible por trombina con xten y usos del mismo.
US10947269B2 (en) 2013-08-08 2021-03-16 Bioverativ Therapeutics Inc. Purification of chimeric FVIII molecules
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
EP3060242A1 (en) 2013-10-22 2016-08-31 DBV Technologies Method of treating haemophilia by inducing tolerance to blood factors
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
EP4332839A3 (en) 2013-12-06 2024-06-05 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
EP2881463A1 (en) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
CA2935954A1 (en) 2014-01-10 2015-07-16 Biogen Ma Inc. Factor viii chimeric proteins and uses thereof
US20160347787A1 (en) 2014-02-04 2016-12-01 Biogen Ma Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
US20170051041A1 (en) * 2014-02-19 2017-02-23 Kathleen Pratt Factor viii b cell epitope variants having reduced immunogenicity
WO2015132724A1 (en) 2014-03-05 2015-09-11 Pfizer Inc. Improved muteins of clotting factor viii
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
TWI741992B (zh) 2015-08-03 2021-10-11 美商百歐維拉提夫治療公司 因子ｉｘ融合蛋白以及其製備及使用方法
PE20231949A1 (es) * 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
MY205187A (en) 2015-11-13 2024-10-04 Takeda Pharmaceuticals Co Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
SG11201804070XA (en) 2015-11-13 2018-06-28 Baxalta Inc Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
NZ745831A (en) 2016-02-01 2025-07-25 Bioverativ Therapeutics Inc Optimized factor viii genes
EP3476937A4 (en) 2016-06-24 2019-12-04 Mogam Institute for Biomedical Research CHIMERIC PROTEIN WITH FVIII AND VWF FACTORS AND USE THEREOF
KR20240069834A (ko) 2016-12-02 2024-05-20 바이오버라티브 테라퓨틱스 인크. 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
EP3548063A1 (en) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
CA3063204A1 (en) 2017-05-09 2018-11-15 Emory University Clotting factor variants and their use
US12168776B2 (en) 2017-08-09 2024-12-17 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof
US20210038744A1 (en) 2018-02-01 2021-02-11 Bioverativ Therapeutics Inc. Use of lentiviral vectors expressing factor viii
KR20210005608A (ko) 2018-04-04 2021-01-14 시질론 테라퓨틱스, 인크. 이식 가능한 입자 및 관련 방법
CN112512555A (zh) 2018-05-18 2021-03-16 比奥维拉迪维治疗股份有限公司 治疗血友病a的方法
US12091675B2 (en) 2018-07-16 2024-09-17 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant FVIII variants with increased expression
MX2021001599A (es) 2018-08-09 2021-07-02 Bioverativ Therapeutics Inc Moleculas de acido nucleico y sus usos para la terapia genica no viral.
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
TWI851647B (zh) 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
CA3144630A1 (en) 2019-06-19 2020-12-24 Bioverativ Therapeutics Inc. Methods and compositions for treating hemophilia and low bone mineral density with factor viiifc protein
CN114375205A (zh) 2019-06-20 2022-04-19 武田药品工业株式会社 用基于病毒的基因疗法进行治疗的方法
TW202126284A (zh) 2019-09-30 2021-07-16 美商百歐維拉提夫治療公司 慢病毒載體配製物
WO2021119357A2 (en) 2019-12-12 2021-06-17 Baxalta Incorporated Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
TW202208619A (zh) 2020-06-24 2022-03-01 美商百歐維拉提夫治療公司 用於純化病毒載體之方法
TW202246505A (zh) * 2021-03-05 2022-12-01 俄羅斯聯邦商亞那拜恩有限公司 編碼凝血因子ｉｘ蛋白的密碼子優化的核酸及其用途
US11906532B2 (en) 2021-03-31 2024-02-20 Haemonetics Corporation Hemostasis measurement device quality control formulations
US20240269241A1 (en) 2021-06-14 2024-08-15 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
WO2023028456A1 (en) 2021-08-23 2023-03-02 Bioverativ Therapeutics Inc. Optimized factor viii genes
MX2024003963A (es) 2021-09-30 2024-04-29 Bioverativ Therapeutics Inc Acidos nucleicos que codifican polipeptidos factor viii con inmunogenia reducida.
EP4602155A1 (en) 2022-10-11 2025-08-20 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
WO2025008774A1 (en) 2023-07-05 2025-01-09 Takeda Pharmaceutical Company Limited Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
EP0182448A3 (en) 1984-08-24 1987-10-28 Genetics Institute, Inc. Production of factor viii and related products
WO1986006101A1 (en) * 1985-04-12 1986-10-23 Genetics Institute, Inc. Novel procoagulant proteins
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
DK162233C (da) 1989-11-09 1992-03-16 Novo Nordisk As Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii
EP0737746A3 (en) * 1989-12-01 1996-10-23 Pharming B.V. Production of recombinant polypeptides by bovine species and transgenic methods
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US6180371B1 (en) * 1996-06-26 2001-01-30 Emory University Modified factor VIII
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
WO1997003191A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs comprising factor v domains or subdomains
AU6455896A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
EP1319016A4 (en) * 2000-09-19 2006-05-10 Univ Emory MODIFIED FACTOR VIII
AU2002364509A1 (en) * 2001-11-30 2003-06-17 Emory University Factor viii c2 domain variants
US7105745B2 (en) * 2002-12-31 2006-09-12 Thomas & Betts International, Inc. Water resistant electrical floor box cover assembly

Also Published As

Publication number Publication date
HUP0300586A2 (hu) 2003-06-28
PL359672A1 (en) 2004-09-06
LU93049I2 (fr) 2016-06-27
US7122634B2 (en) 2006-10-17
NO20024296L (no) 2002-11-08
PL202936B1 (pl) 2009-08-31
SK14392002A3 (sk) 2003-06-03
UA75064C2 (en) 2006-03-15
NO2016007I2 (no) 2016-05-10
CY1108179T1 (el) 2014-02-12
DK1280540T3 (da) 2008-07-14
US7012132B2 (en) 2006-03-14
SK286205B6 (sk) 2008-05-06
HUS1600020I1 (hu) 2016-06-28
US6458563B1 (en) 2002-10-01
CZ298250B6 (cs) 2007-08-01
JP4044337B2 (ja) 2008-02-06
ATE391512T1 (de) 2008-04-15
EE05075B1 (et) 2008-10-15
HU227804B1 (en) 2012-03-28
BRPI0109131B1 (pt) 2020-08-25
BRPI0109131B8 (pt) 2021-07-06
NL300808I2 (nl) 2020-12-21
CZ20023346A3 (cs) 2003-01-15
DE60133541D1 (de) 2008-05-21
BR122013026957A8 (pt) 2017-02-21
IL151371A (en) 2010-12-30
RS50364B (sr) 2009-11-10
NO20024296D0 (no) 2002-09-09
RU2285724C2 (ru) 2006-10-20
JP2003526358A (ja) 2003-09-09
BR122013026957A2 (OSRAM) 2004-12-07
KR20020081426A (ko) 2002-10-26
NL300808I1 (OSRAM) 2016-05-18
DE60133541T2 (de) 2009-05-07
CA2400295A1 (en) 2001-09-20
BE2016C024I2 (OSRAM) 2020-01-30
YU68002A (sh) 2005-11-28
EE200200510A (et) 2004-02-16
EP1280540B1 (en) 2008-04-09
ME00601B (me) 2011-12-20
US20030068785A1 (en) 2003-04-10
US20050079584A1 (en) 2005-04-14
ZA200206810B (en) 2003-11-26
CN1191360C (zh) 2005-03-02
FR16C0016I1 (OSRAM) 2016-04-29
EP1280540A1 (en) 2003-02-05
CY2016011I1 (el) 2016-10-05
IL151371A0 (en) 2003-04-10
NO2016007I1 (no) 2016-05-10
KR100485525B1 (ko) 2005-04-28
RU2002124123A (ru) 2004-03-27
NZ520799A (en) 2004-06-25
AU2001238416B2 (en) 2004-09-02
CY2016011I2 (el) 2016-10-05
NO331935B1 (no) 2012-05-07
PT1280540E (pt) 2008-06-09
FR16C0016I2 (fr) 2018-11-02
HK1051004A1 (en) 2003-07-18
MEP8209A (en) 2011-12-20
CA2400295C (en) 2012-01-10
ES2304379T3 (es) 2008-10-16
EP1280540A4 (en) 2004-11-03
BR0109131A (pt) 2004-12-07
CN1416348A (zh) 2003-05-07
HUP0300586A3 (en) 2006-11-28
SI1280540T1 (sl) 2008-08-31
MXPA02008798A (es) 2003-04-25
AU3841601A (en) 2001-09-24
WO2001068109A1 (en) 2001-09-20

Similar Documents

Publication Publication Date Title
NO2016007I1 (no) Susoktokog
PT1200105E (pt) Factor viii modificado
DK1200418T3 (da) Nematodicide trifluorbutener
DE50012238D1 (de) Desinfizierendes waschen empfindlicher textilien mit persäuren
DE60101265D1 (de) Behandlung von augenschmerzen
EA200300717A1 (ru) Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
ATE250605T1 (de) Piperidin verbindung zur behandlung von psoriasis
MXPA04005079A (es) Variantes del dominio c2 del factor viii.
CY1106026T1 (el) Αρυλσουλφοναμιδια ως ανταγωνιστες της σepοτονινης για την αγωγη της παχυσαρκιας
NO20025405D0 (no) Modulatorer for TNF-alfa-signalisering
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
MX9403032A (es) Quinolil-dihidropiridinas condensadas, procedimiento para su fabricacion ysu uso en medicamentos.
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
CY1105142T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
CY1105317T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
DE60009315D1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
ATE390144T1 (de) Behandlung von fibrosen
MXPA01009174A (es) Antagonistas de endotelina novedosos derivados de piridazina.